Northern Trust Corp grew its stake in Calithera Biosciences Inc (NASDAQ:CALA) by 1,355.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 337,640 shares of the biotechnology company’s stock after buying an additional 314,436 shares during the quarter. Northern Trust Corp owned approximately 0.96% of Calithera Biosciences worth $5,014,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of CALA. Vanguard Group Inc. boosted its stake in Calithera Biosciences by 99.8% during the first quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock valued at $10,684,000 after buying an additional 462,137 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Calithera Biosciences by 608.7% in the 2nd quarter. Acadian Asset Management LLC now owns 233,956 shares of the biotechnology company’s stock valued at $3,474,000 after purchasing an additional 200,946 shares during the last quarter. Artal Group S.A. bought a new stake in shares of Calithera Biosciences in the 2nd quarter valued at approximately $2,970,000. TIAA CREF Investment Management LLC bought a new stake in shares of Calithera Biosciences in the 2nd quarter valued at approximately $2,727,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Calithera Biosciences by 729.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 133,981 shares of the biotechnology company’s stock valued at $1,547,000 after purchasing an additional 117,832 shares during the last quarter. Institutional investors and hedge funds own 72.19% of the company’s stock.
CALA has been the topic of several recent analyst reports. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Monday, November 6th. William Blair initiated coverage on Calithera Biosciences in a report on Thursday, October 5th. They issued an “outperform” rating on the stock. ValuEngine downgraded Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Friday. Finally, BidaskClub upgraded Calithera Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Calithera Biosciences currently has an average rating of “Hold” and a consensus target price of $15.17.
Shares of Calithera Biosciences Inc (NASDAQ CALA) traded down $0.60 during trading hours on Monday, hitting $9.75. The stock had a trading volume of 564,972 shares, compared to its average volume of 745,145. Calithera Biosciences Inc has a twelve month low of $2.90 and a twelve month high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.02 million. sell-side analysts anticipate that Calithera Biosciences Inc will post -0.77 earnings per share for the current fiscal year.
In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of Calithera Biosciences stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $15.64, for a total transaction of $9,008,640.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 16.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Northern Trust Corp Boosts Holdings in Calithera Biosciences Inc (NASDAQ:CALA)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/northern-trust-corp-acquires-314436-shares-of-calithera-biosciences-inc-cala.html.
Calithera Biosciences Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.